Bitter pills: on Court’s intervention, drug pricing

Published 2026-10-01 · Updated 2026-10-01 · 3 min · 603 words

UPSC CSE Context

Why in News

Supreme Court flags up to 1,000% disparity between price to retailer and MRP of cancer drugs, urging regulatory action.

Syllabus Connection

GS Paper 2: Health, Government policies and interventions; GS Paper 3: Issues related to intellectual property rights, pricing.

Exam Relevance

High relevance for questions on pharmaceutical regulation, health economics, and judicial intervention in market failures.

Core Issue

Hospitals exploit drug pricing gap to profit at patients' expense.

Key Development

Supreme Court directs government to address inflated MRPs and trade margin exploitation in cancer drugs.

Stakeholders

• National Pharmaceutical Pricing Authority (NPPA)
• Department of Pharmaceuticals
• Pharmaceutical companies
• Competition Commission of India
• Drug regulators in Karnataka and Maharashtra

Static Knowledge

High-Value Background

• Drug (Prices Control) Order 2013 caps prices of scheduled drugs but not trade margins.
• NPPA regulates drug prices and can cap trade margins under special circumstances.

Exam Linkage

• Useful for questions on regulatory gaps in healthcare and judicial oversight of executive inaction.

Concepts in Context

• Price to retailer (PTR) is the price at which manufacturers sell to hospitals/pharmacies.
• Maximum retail price (MRP) is the ceiling price inclusive of all taxes, set by manufacturers.

Institutions and Mechanisms

• NPPA is empowered to fix ceiling prices of scheduled drugs under DPCO 2013.

Dynamic Analysis

Health Economics

• Trade margin exploitation distorts price signals, leading to overpricing of essential medicines.
• Hospitals act as gatekeepers, reducing patient choice and enabling rent-seeking.
• High out-of-pocket expenditure on drugs contributes to catastrophic health spending.
• Lack of transparency in PTR-MRP gap undermines market efficiency.

Regulatory Governance

• DPCO 2013's focus on ceiling prices ignores trade margins, creating a regulatory loophole.
• NPPA's 2019 pilot on trade margin capping showed significant price reductions, but was not scaled up.
• Fragmented regulatory oversight between Centre and States hampers effective enforcement.
• Need for dynamic price regulation that accounts for market distortions.

Judicial Intervention

• Supreme Court's proactive stance fills a governance vacuum in drug pricing.
• Judicial directives can compel executive action but risk overstepping into policy domain.
• Court's refusal to intervene in Siddharth Dalmia (2025) contrasts with current intervention, indicating selective engagement.
• Judicial oversight may be necessary when regulatory bodies fail to protect public interest.

Patient Welfare

• Cancer patients face severe financial strain due to inflated drug prices.
• High costs may lead to non-adherence to treatment regimens, worsening health outcomes.
• Patients in private hospitals are often forced to buy from in-house pharmacies, limiting price comparison.
• Vulnerable populations bear disproportionate burden of exploitative pricing.

Prelims Takeaways

• NPPA capped trade margins of 42 non-schedule anti-cancer drugs at 30% in 2019.

Mains Value Addition

Arguments

• Trade margin regulation is essential to curb exploitative pricing in healthcare.
• Judicial intervention highlights systemic regulatory failure in pharmaceutical pricing.
• Need for a comprehensive drug pricing policy that addresses both ceiling prices and trade margins.
• Market distortions in healthcare require multi-pronged regulatory and competition law interventions.

Examples

• NPPA's 2019 pilot on 42 anti-cancer drugs led to price drops of up to 91% for 526 brands.

Data Points

• Supreme Court noted PTR-MRP disparity up to 1,000% for some cancer drugs.
• NPPA's 2019 trade margin cap of 30% on 42 non-schedule anti-cancer drugs.

Counterpoints

• Fixed percentage markup across all drugs may not account for varying distribution costs.
• Regressive margin approach may be complex to implement and monitor.
• Pharmaceutical industry may resist trade margin regulation, citing innovation disincentives.

Way Forward

• Amend DPCO 2013 to include trade margin regulation for all drugs.
• Implement regressive trade margins: lower percentage for higher-priced drugs.
• Strengthen NPPA's mandate and capacity for effective price monitoring and enforcement.
• Promote transparency by mandating disclosure of PTR and actual transaction prices.
• Enhance competition in hospital pharmacy services to prevent forced purchases.

Primary/reference source: thehindu.com